DGAP-News: Biotest AG: Biotest increases adjusted 9-month EBIT by over 21% to € 52 million
In the first nine months of the 2020 financial year, the Biotest Group recorded adjusted EBIT of 51.6 million.
- In the first nine months of the 2020 financial year, the Biotest Group recorded adjusted EBIT of 51.6 million.
- The adjusted EBIT does not include the costs for the Biotest Next Level expansion project in the amount of 59.3 million (same period of the previous year: 49.7 million).
- The adjusted EBIT margin rose to 15.1 % in the first nine months of the current fiscal year, compared to 14.4 % in the same period last year.
- Based on the aforementioned factors, the Board of Management expects EBIT to be between -10 million and -5 million.